Abstract
Recently mitochondria in cancer cells have emerged as the Achilles heel for tumour destruction. Anti-cancer agents specifically targeting cancer cell mitochondria are referred to as ‘mitocans’. These compounds act by destabilising these organelles, unleashing their apoptogenic potential, resulting in the efficient death of malignant cells and suppression of tumour growth. Importantly, at least some mitocans are selective for cancer cells, and these are represented by the group of redox-silent vitamin E analogues, epitomised by α-tocopheryl succinate (α-TOS). This compound has proven itself in pre-clinical models to be an efficient anti-cancer agent, targeting complex II of the respiratory chain to displace ubiquinone binding. We propose that disrupting the electron flow of mitochondrial complex II results in generation of superoxide, triggering mitochondrial destabilisation and initiation of apoptotic pathways. Moreover, α-TOS is selective for cancer cells with their reduced anti-oxidant defenses and lower esterase activity than the normal (non-malignant) counterparts. In this mini-review we discuss the emerging significance of mitocans, as exemplified by α-TOS.
Similar content being viewed by others
References
Albayrak T, Scherhammer V, Schoenfeld N, Braziulis E, Mund T, Bauer MK, Scheffler IE, Grimm S (2003) Mol Biol Cell 14:3082–3096
Amadori S, Fenaux P, Ludwig H, O’dwyer M, Sanz M (2005) Curr Med Res Opin 21:403–411
Antonsson B, Montessuit S, Sanchez B, Martinou JC (2001) J Biol Chem 276:11615–11623
Belzacq AS, El Hamel C, Vieira HL, Cohen I, Haouzi D, Metivier D, Marchetti P, Brenner C, Kroemer G (2001) Oncogene 20:7579–7587
Birringer M, EyTina JH, Salvatore BA, Neuzil J (2003) Br J Cancer 88:1948–1955
Borrello S, De Leo ME, Galeotti T (1993) Mol Aspects Med 14:253–258
Cartron PF, Arokium H, Oliver L, Meflah K, Manon S, Vallette FM (2005) J Biol Chem 280:10587–10598
Cory S, Adams JM (2002) Nat Rev Cancer 2:647–656
Degterev A, Lugovskoy A, Cardone M, Mulley B, Wagner G, Mitchison T, Yuan J (2001) Nat Cell Biol 3:173–182
Di Cosimo S, Ferretti G, Papaldo P, Carlini P, Fabi A, Cognetti F (2003) Drugs Today 39:157–174
Don AS, Kisker O, Dilda P, Donoghue N, Zhao X, Decollogne S, Creighton B, Flynn E, Folkman J, Hogg PJ (2003) Cancer Cell 3:497–509
Dong LF, Wang XF, Zhao Y, Tomasetti M, Wu K, Neuzil J (2006) Cancer Ther 4:35–46
Fantin VR, Leder P (2006) Oncogene 25:4787–4797
Freeman R, Neuzil J (2006) FEBS Lett 580:2671–2676
Galluzzi L, Larochette N, Zamzami N, Kroemer G (2006) Oncogene 25:4812–4830
Gelinas C, White E (2005) Genes Dev 19:1263–1268
Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL (2002) Cancer Res 62:3909–3913
Gottlieb E, Tomlinson IP (2005) Nat Rev Cancer 5:857–866
Ishii T, Yasuda K, Akatsuka A, Hino O, Hartman PS, Ishii N (2005) Cancer Res 65:203–209
James AM, Cocheme HM, Smith RA, Murphy MP (2005) J Biol Chem 280:21295–21312
Kagan VE, Tyurin VA, Jiang J, Tyurina YY, Ritov VB, Amoscato AA, Osipov AN, Belikova NA, Kapralov AA, Kini V, Vlasova II, Zhao Q, Zou M, Di P, Svistunenko DA, Kurnikov IV, Borisenko GG (2005) Nat Chem Biol 1:223–232
Kang YH, Lee E, Choi MK, Ku JL, Kim SH, Park YG, Lim SJ (2004) Int J Cancer 112:385–392
Kelso GF, Porteous CM, Coulter CV, Hughes G, Porteous WK, Ledgerwood EC, Smith RA, Murphy MP (2001) J Biol Chem 276:4588–4596
Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, Hullihen J, Pedersen PL, Biochem Biophys Res Commun 324:269–275
Kogure K, Hama S, Manabe S, Tokumura A, Fukuzawa K (2002) Cancer Lett 186:151–156
Kogure K, Morita M, Nakashima S, Hama S, Tokumura A, Fukuzawa K (2001) Biochim Biophys Acta 1528:25–30
Korsmeyer SJ, Wei MC, Saito M, Weiler S, Oh KJ, Schlesinger PH (2000) Cell Death Differ 7:1166–1173
Leonard JV, Schapira AH (2000) Lancet 355:389–394
Li J, Lee B, Lee AS (2006) J Biol Chem 281:7260–7270
Makin GW, Corfe BM, Griffiths GJ, Thistlethwaite A, Hickman JA, Dive C (2001) EMBO J 20:6306–6315
McLennan HR, Degli-Esposti M (2000) J Bioenerg Biomembr 32:153–162
Ming L, Wang P, Bank A, Yu J, Zhang L (2006) J Biol Chem 281:16034–16042
Neuzil J, Schröder A, von Hundelshausen P, Zernecke A, Weber T, Gellert N, Weber C (2001) Biochemistry 40:4686–4692
Neuzil J, Tomasetti M, Mellick AS, Alleva R, Salvatore BA, Birringer B, Fariss MW (2004) Curr Cancer Drug Targets 4:267–284
Neuzil J, Wang XF, Dong LF, Low P, Ralph SJ (2006) FEBS Lett 580:5125–5129
Neuzil J, Weber T, Gellert N, Weber C (2001) Br J Cancer 84:87–89
Neuzil J, Weber T, Schröder A, Lu M, Ostermann G, Gellert N, Mayne GC, Olejnicka B, Nègre-Salvayre A, Sticha M, Coffey RJ, Weber C (2001) FASEB J 15:403–415
Newmeyer DD, Ferguson-Miller S (2003) Cell 112:481–490
O’Neill J, Manion M, Schwartz P, Hockenbery DM (2004) Biochim Biophys Acta 1705:43–51
Oostveen FG, Au HC, Meijer PJ, Scheffler IE (1995) J Biol Chem 270:26104–26108
Ott M, Robertson JD, Gogvadze V, Zhivotovsky B, Orrenius S (2002) Proc Natl Acad Sci USA 99:1259–1263
Ottino P, Duncan JR (1997) Free Radic Biol Med 22:1145–1151
Patenaude A, Ven Murthy MR, Mirault ME (2004) J Biol Chem 279:27302–27314
Pelicano H, Martin DS, Xu RH, Huang P (2006) Oncogene 25:633–4646
Petrosillo G, Ruggiero FM, Pistolese M, Paradies G (2001) FEBS Lett 509:435–438
Raha S, Robinson BH (2000) Trends Biochem Sci 25:502–508
Ralph SJ, Dong LF, Low P, Lawen A, Neuzil J (2006) Recent Patent Reviews Anti-Cancer Drug Discovery (in press)
Ravagnan L, Marzo I, Costantini P, Susin SA, Zamzami N, Petit PX, Hirsch F, Goulbern M, Poupon MF, Miccoli L, Xie Z, Reed JC, Kroemer G (1999) Oncogene 18:2537–2546
Reed JC (2006) Cell Death Differ 13:1378–1386
Reed JC, Pellecchia M (2005) Blood 106:408–418
Robey RB, Hay N (2005) Cell Cycle 4:654–658
Rotem R, Heyfets A, Fingrut O, Blickstein D, Shaklai M, Flescher E (2005) Cancer Res 65:1984–1993
Schumacker PT (2006) Cancer Cell 10:175–176
Seo BB, Kitajima-Ihara T, Chan EK, Scheffler IE, Matsuno-Yagi A, Yagi T (1998) Proc Natl Acad Sci USA 95:9167–9171
Shiau CW, Huang JW, Wang DS, Weng JR, Yang CC, Lin CH, Li C, Chen CS (2006) J Biol Chem 281:11819–11825
Stapelberg M, Gellert N, Swettenham E, Tomasetti M, Witting PK, Procopio A, Neuzil J (2005) J Biol Chem 280, 25369–25376
Sun F, Huo X, Zhai Y, Wang A, Xu J, Su D, Bartlam M, Rao Z (2005) Cell 121:1043–1057
Sun Y, Oberley LW (1996) Free Radic Biol Med 21:335–348
Swettenham E, Witting PK, Salvatore BA, Neuzil J (2005) J Neurochem 94:1448–1456
Tomasetti M, Andera L, Alleva R, Borghi B, Neuzil J, Procopio A (2006) FEBS Lett 580:1925–1931
Tomic-Vatic A, EyTina JH, Chapmann JM, Mahdavian E, Neuzil J, Salvatore BA (2005) Int J Cancer 117:118–193
Wang XF, Dong LF, Zhao Y, Tomasetti M, Wu K, Neuzil J (2006) Mol Nutr Food Res 50:675–685
Wang K, Gross A, Waksman G, Korsmeyer SJ (1998) Mol Cell Biol 18:6083–6089
Weber T, Dalen H, Andera L, Nègre-Salvayre A, Augé N, Sticha M, Loret A, Terman A, Witting PK, Higuchi M, Plasilova M, Zivny J, Gellert N, Weber C, Neuzil J (2003) Biochemistry 42:4277–4291
Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, Adams JM, Huang DC (2005) Genes Dev 19:1294–1305
Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG, Youle RJ (1997) J Cell Biol 139:1281–1292
Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Keating MJ, Huang P (2005) Cancer Res 65:613–621
Yin H, Lee GI, Sedey KA, Kutzki O, Park HS, Orner BP, Ernst JT, Wang HG, Sebti SM, Hamilton AD (2005) J Am Chem Soc 127:10191–10196
Yoo MH, Xu XM, Carlson BA, Gladyshev VN, Hatfield DL (2006) J Biol Chem 281:13005–13008
Yu W, Sanders BG, Kline K (2003) Cancer Res 63:2483–2491
Zha A, Aime-Sempe C, Sato T, Reed JC (1996) J Biol Chem 271:7440–7444
Zhao K, Zhao GM, Wu D, Soong Y, Birk AV, Schiller PW, Szeto HH (2004) J Biol Chem 279:34682–34690
Zhivotovsky B, Orrenius S, Brustugun OT, Doskeland SO (1998) Nature 391:449–450
Author information
Authors and Affiliations
Corresponding author
Additional information
Lubomir Prochazka is a visiting student of the Apoptosis Research Group, School of Medical Science, Griffith University, Southport, Qld, Australia.
Rights and permissions
About this article
Cite this article
Neuzil, J., Dyason, J.C., Freeman, R. et al. Mitocans as anti-cancer agents targeting mitochondria: lessons from studies with vitamin E analogues, inhibitors of complex II. J Bioenerg Biomembr 39, 65–72 (2007). https://doi.org/10.1007/s10863-006-9060-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10863-006-9060-z